Literature DB >> 16081048

Evaluation of potential Stat3-regulated genes in human breast cancer.

Fu-Chuan Hsieh1, Gong Cheng, Jiayuh Lin.   

Abstract

The constitutive activation of signal transducer and activator of transcription 3 (Stat3) is frequently detected in breast cancer tissues and cell lines. Stat3 has been classified as a proto-oncogene, because an activated form of Stat3 can mediate oncogenic transformation in cultured cells and tumor formation in nude mice. Since Stat3 may play an important role in breast cancer, it is of interest to investigate the expression of phosphorylated Stat3, an activated form of Stat3, and its downstream mediators specifically in breast cancer, and to explore the possible mechanisms of Stat3 signaling pathway in oncogenesis of breast cancer. We analyzed Stat3 phosphorylation and expression of Stat3-regulated genes in breast cancer cell lines as well as invasive breast cancer tissues using tissue microarray slides. Our results showed that elevated levels of phosphorylation of Stat3 protein (Tyr705) were detected in 48 out of total 136 invasive breast tumors (35%) whereas normal breast tissues express much lower levels of Stat3 phosphorylation. The increased levels of Stat3 phosphorylation were associated with the metastasis in regional lymph nodes (P=0.042) and the expression of progesterone receptor (P=0.028) but not with distant metastasis, nor the expression of estrogen receptor. Our results also indicate that elevated levels of Stat3 phosphorylation were significantly associated with increased expression of potential downstream targets of Stat3 which include apoptosis inhibitors (Survivin, Mcl-1, HSP27, Adrenomedullin, and Bcl-xL), cell-cycle regulators (c-Fos, MEK5, and c-Myc), and inducer of tumor angiogenesis (VEGF, COX-2, MMP-2, MMP-10, and MMP-1) in invasive breast cancer tissues. Therefore, our findings suggest that constitutive Stat3 signaling may be one of the key upstream regulators to induce these downstream proteins, which may play important roles in Stat3-mediated oncogenesis in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081048     DOI: 10.1016/j.bbrc.2005.07.075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  81 in total

1.  B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.

Authors:  Hao Liu; Christina Tekle; Yih-Wen Chen; Alexandr Kristian; Yuhua Zhao; Ming Zhou; Zixing Liu; Yan Ding; Bin Wang; Gunhild Mari Mælandsmo; Jahn Marthin Nesland; Oystein Fodstad; Ming Tan
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

2.  JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Susan A Kadlubar; Kristina L Bondurant; Roger K Wolff
Journal:  Mol Carcinog       Date:  2011-11-28       Impact factor: 4.784

3.  Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.

Authors:  Joomin Lee; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Carcinogenesis       Date:  2010-08-19       Impact factor: 4.944

4.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer.

Authors:  Jennifer Dien; Hesham M Amin; Neil Chiu; Winson Wong; Christine Frantz; Brian Chiu; John R Mackey; Raymond Lai
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  BOOTSTRAP INFERENCE FOR NETWORK CONSTRUCTION WITH AN APPLICATION TO A BREAST CANCER MICROARRAY STUDY.

Authors:  Shuang Li; Li Hsu; Jie Peng; Pei Wang
Journal:  Ann Appl Stat       Date:  2013-03-01       Impact factor: 2.083

6.  Effect of niclosamide on basal-like breast cancers.

Authors:  Angelina I Londoño-Joshi; Rebecca C Arend; Laura Aristizabal; Wenyan Lu; Rajeev S Samant; Brandon J Metge; Bertha Hidalgo; William E Grizzle; Michael Conner; Andres Forero-Torres; Albert F Lobuglio; Yonghe Li; Donald J Buchsbaum
Journal:  Mol Cancer Ther       Date:  2014-02-19       Impact factor: 6.261

Review 7.  Anti-cancer therapies that utilize cell penetrating peptides.

Authors:  Benjamin G Bitler; Joyce A Schroeder
Journal:  Recent Pat Anticancer Drug Discov       Date:  2010-06       Impact factor: 4.169

Review 8.  Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.

Authors:  Sarah R Walker; Michael Xiang; David A Frank
Journal:  Mol Cell Endocrinol       Date:  2013-03-24       Impact factor: 4.102

9.  Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.

Authors:  Hoyee Leong; Priya S Mathur; Geoffrey L Greene
Journal:  Breast Cancer Res Treat       Date:  2008-09-28       Impact factor: 4.872

10.  Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.

Authors:  Walid Sasi; Wen G Jiang; Anup Sharma; Kefah Mokbel
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.